PureTech Health, an advanced biopharmaceutical company developing novel medicines for dysfunctions of the Brain-Immune-Gut axis, has acquired and is planning to develop a clinical-stage product candidate, LYT-100, for the potential treatment of lymphatic and immunofibrotic diseases, including lymphedema, it was reported yesterday.

In preclinical studies, the oral, small molecule candidate, LYT-100, indicated anti-fibrotic and anti-inflammatory mechanisms, and in a Phase one clinical trial in healthy volunteers, LYT-100 was observed to be well tolerated with a favourable pharmacokinetic profile to support twice daily oral dosing.

The product expands the company's internal R&D range and continues its progress in developing new medicines based on insights into the lymphatic system and local modulation of the immune system for the treatment of immune and central nervous system disorders, lymphatic conditions, and cancers. It is an oral small molecule with well-established preclinical anti-fibrotic activity that has been earlier studied in healthy volunteers as part of a Phase one, single ascending dose study.